Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin after R-CVP in Follicular Lymphoma
NCT00384111Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Oct 2006
- Primary completion
- Nov 2008
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by Spectrum Pharmaceuticals, Inc.. Started Oct 2006; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00384111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384111.